Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albumin + furosemide is a combination therapy involving the co-administration of human serum albumin and the loop diuretic furosemide. This regimen is primarily used in patients with edema who are resistant to diuretics alone, particularly those with hypoalbuminemia (low serum albumin levels), such as in nephrotic syndrome, liver cirrhosis, or chronic kidney disease. Albumin increases plasma oncotic pressure and expands intravascular volume, while furosemide inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle, promoting diuresis. The combination enhances delivery of furosemide to its site of action by increasing its binding to albumin and facilitating secretion into renal tubules. Clinical studies suggest that this combination can increase urine output and natriuresis more effectively than either agent alone in select populations[1][2][5][7]. However, response varies among patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albumin + furosemide.